lactic acid has been researched along with Hemolysis in 84 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Hemolysis: The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " BJ rats showed markedly reduced glomerular filtration rate (GFR, inulin clearance) associated with intense renal vasoconstriction, hemolysis, hemoglobinuria, reduced glutathione and increased systemic and renal markers of nitro-oxidative stress (Nitrotyrosine)." | 7.85 | Allopurinol attenuates acute kidney injury following Bothrops jararaca envenomation. ( Canale, D; Crajoinas, R; Ferreira, D; Girardi, ACC; Gois, PHF; Malaque, C; Martines, MS; Massola Shimizu, MH; Seguro, AC; Volpini, R, 2017) |
| "The experiments test if experimental PE causes red blood cell hemolysis, arginase release and depletion of l-arginine and determine if arginase inhibition preserves l-arginine and improves pulmonary hemodynamics during PE." | 7.78 | Arginase depletes plasma l-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism. ( Das, SK; Fulkerson, MB; Gellar, MA; Kline, JA; Watts, JA, 2012) |
| " The hemolysis index, lactate and potassium concentrations, prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen were measured on plasma aliquots." | 3.88 | In vitro assessment of quality of citrate-phosphate-dextrose-adenine-1 preserved feline blood collected by a commercial closed system. ( Bozzato, E; Capello, K; Carminato, A; Corrò, M; Crestani, C; Cro, A; Mutinelli, F; Stefani, A; Vascellari, M, 2018) |
| " BJ rats showed markedly reduced glomerular filtration rate (GFR, inulin clearance) associated with intense renal vasoconstriction, hemolysis, hemoglobinuria, reduced glutathione and increased systemic and renal markers of nitro-oxidative stress (Nitrotyrosine)." | 3.85 | Allopurinol attenuates acute kidney injury following Bothrops jararaca envenomation. ( Canale, D; Crajoinas, R; Ferreira, D; Girardi, ACC; Gois, PHF; Malaque, C; Martines, MS; Massola Shimizu, MH; Seguro, AC; Volpini, R, 2017) |
| "The experiments test if experimental PE causes red blood cell hemolysis, arginase release and depletion of l-arginine and determine if arginase inhibition preserves l-arginine and improves pulmonary hemodynamics during PE." | 3.78 | Arginase depletes plasma l-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism. ( Das, SK; Fulkerson, MB; Gellar, MA; Kline, JA; Watts, JA, 2012) |
| "Melatonin is an endogen substance with several physiological functions, acting as an important antioxidant." | 1.48 | PLGA Nanoparticles and Polysorbate-80-Coated PLGA Nanoparticles Increase the In vitro Antioxidant Activity of Melatonin. ( Khalil, NM; Mainardes, RM; Martins, LG, 2018) |
| " Thus, there is a need to develop a formulation which can eliminate the need of frequent dosing and enhance patient's acquiescence." | 1.48 | Hepatitis B Antigen Loaded Biodegradable Polymeric Nanoparticles: Formulation Optimization and In-vivo Immunization in BALB/c Mice. ( Dewangan, HK; Maurya, L; Singh, S; Srivastava, A, 2018) |
| " There is currently an unmet need for an efficacious (AMB) formulation amenable to oral administration with better bioavailability and lower nephrotoxicity." | 1.46 | Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats. ( AlQuadeib, BT; Horrocks, B; Radwan, MA; Šiller, L; Wright, MC, 2017) |
| "The development of antibacterial drugs to overcome various pathogenic species, which inhabit the oral cavity, faces several challenges, such as salivary flow and enzymatic activity that restrict dosage retention." | 1.43 | Sustained Release of Antibacterial Lipopeptides from Biodegradable Polymers against Oral Pathogens. ( Bachrach, G; Beyth, N; Beyth, S; Domb, AJ; Eckhard, LH; Houri-Haddad, Y; Shai, Y; Sol, A; Zeharia, R, 2016) |
| "Hemolysis is common in all extracorporeal circuits as evident by the elevated plasma free hemoglobin (PFHb) level." | 1.42 | Plasma Free Hemoglobin Is an Independent Predictor of Mortality among Patients on Extracorporeal Membrane Oxygenation Support. ( Caldeira, C; Camporesi, EM; Mangar, D; Mirsaeidi, M; Omar, HR; Socias, S; Sprenker, C, 2015) |
| "Mitomycin C (MMC) is a water-soluble anticancer drug extensively used in first-line chemotherapy but is limited by its poor aqueous stability in vitro, rapid elimination from the body, and lack of target specificity." | 1.40 | Mitomycin C-soybean phosphatidylcholine complex-loaded self-assembled PEG-lipid-PLA hybrid nanoparticles for targeted drug delivery and dual-controlled drug release. ( Hou, Z; Huang, Y; Jia, M; Li, Y; Lin, J; Wu, H; Wu, S; Yang, X, 2014) |
| "Amphotericin B (AmB) is a broad spectrum antifungal and antileishmenial agent and its clinical use is limited due to substantial dose limiting toxicities such as nephrotoxicity." | 1.36 | Development of amphotericin B loaded polymersomes based on (PEG)(3)-PLA co-polymers: Factors affecting size and in vitro evaluation. ( Jain, JP; Kumar, N, 2010) |
| "3%) and severe nephrotoxicity, was entrapped into poly(lactide-co-glycolide) (PLGA) nanoparticles to improve the oral bioavailability and to minimize the adverse effects associated with it." | 1.35 | Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone. ( Italia, JL; Ravi Kumar, MN; Singh, D; Yahya, MM, 2009) |
| " The pharmacokinetic profiles of ITZ-PM for itraconazole and its major metabolite, hydroxy-itraconazole, were comparable to those of the cyclodextrin formulations (Sporanox(R) Injection and Oral Solution) in rats and dogs." | 1.34 | A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics. ( Hwang, SJ; Kim, BO; Kim, SO; Seo, MH; Shim, M; Yi, Y; Yoon, HJ, 2007) |
| "The lactic acid was injected to rabbit through the auricular vein till the final concentration for the circulating blood was 0." | 1.30 | Effect of lactic acid on water content and osmotic fragility of erythrocytes in vivo. ( Higuchi, T; Kageyama, K; Kogawa, H; Mitsudo, M; Satoh, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (5.95) | 18.7374 |
| 1990's | 8 (9.52) | 18.2507 |
| 2000's | 14 (16.67) | 29.6817 |
| 2010's | 56 (66.67) | 24.3611 |
| 2020's | 1 (1.19) | 2.80 |
| Authors | Studies |
|---|---|
| Vardaki, MZ | 1 |
| Schulze, HG | 1 |
| Serrano, K | 2 |
| Blades, MW | 1 |
| Devine, DV | 2 |
| Turner, RFB | 1 |
| Sahu, P | 1 |
| Kashaw, SK | 1 |
| Jain, S | 2 |
| Sau, S | 1 |
| Iyer, AK | 1 |
| Bardyn, M | 1 |
| Rappaz, B | 1 |
| Jaferzadeh, K | 1 |
| Crettaz, D | 1 |
| Tissot, JD | 1 |
| Moon, I | 1 |
| Turcatti, G | 1 |
| Lion, N | 1 |
| Prudent, M | 1 |
| Martins, LG | 1 |
| Khalil, NM | 1 |
| Mainardes, RM | 1 |
| Gois, PHF | 1 |
| Martines, MS | 1 |
| Ferreira, D | 1 |
| Volpini, R | 1 |
| Canale, D | 1 |
| Malaque, C | 1 |
| Crajoinas, R | 1 |
| Girardi, ACC | 1 |
| Massola Shimizu, MH | 1 |
| Seguro, AC | 1 |
| Crestani, C | 1 |
| Stefani, A | 1 |
| Carminato, A | 1 |
| Cro, A | 1 |
| Capello, K | 1 |
| Corrò, M | 1 |
| Bozzato, E | 1 |
| Mutinelli, F | 1 |
| Vascellari, M | 1 |
| Dewangan, HK | 1 |
| Singh, S | 1 |
| Maurya, L | 1 |
| Srivastava, A | 1 |
| Proffitt, S | 1 |
| Curnow, E | 1 |
| Brown, C | 1 |
| Bashir, S | 1 |
| Cardigan, R | 2 |
| Larsson, L | 2 |
| Larsson, S | 1 |
| Derving, J | 1 |
| Watz, E | 1 |
| Uhlin, M | 1 |
| Qiao, H | 1 |
| Li, J | 2 |
| Wang, Y | 2 |
| Ping, Q | 1 |
| Wang, G | 1 |
| Gu, X | 1 |
| Arunraj, TR | 1 |
| Sanoj Rejinold, N | 1 |
| Ashwin Kumar, N | 1 |
| Jayakumar, R | 1 |
| Gupta, M | 1 |
| Chashoo, G | 1 |
| Sharma, PR | 1 |
| Saxena, AK | 1 |
| Gupta, PN | 2 |
| Agrawal, GP | 2 |
| Vyas, SP | 1 |
| Winter, KM | 1 |
| Johnson, L | 1 |
| Kwok, M | 1 |
| Vidovic, D | 1 |
| Hyland, RA | 1 |
| Mufti, N | 1 |
| Erickson, A | 1 |
| Marks, DC | 1 |
| Lv, L | 1 |
| Shen, Y | 2 |
| Li, M | 2 |
| Xu, X | 2 |
| Guo, S | 1 |
| Huang, S | 1 |
| He, Z | 1 |
| Wang, Q | 2 |
| Sun, Y | 1 |
| Shen, M | 1 |
| Zhu, M | 1 |
| Gu, M | 1 |
| Duan, Y | 1 |
| Sathler, PC | 1 |
| Lourenço, AL | 1 |
| Rodrigues, CR | 1 |
| da Silva, LC | 1 |
| Cabral, LM | 1 |
| Jordão, AK | 1 |
| Cunha, AC | 1 |
| Vieira, MC | 1 |
| Ferreira, VF | 1 |
| Carvalho-Pinto, CE | 1 |
| Kang, HC | 1 |
| Castro, HC | 1 |
| Mercado-Pagán, ÁE | 1 |
| Ker, DF | 1 |
| Yang, Y | 1 |
| Nehate, C | 1 |
| Alam, N | 1 |
| Khare, V | 1 |
| Dubey, RD | 1 |
| Saneja, A | 1 |
| Kour, S | 1 |
| Singh, SK | 1 |
| Liu, L | 1 |
| Li, N | 1 |
| Lei, T | 1 |
| Li, K | 1 |
| Zhang, Y | 1 |
| Li, L | 1 |
| Li, H | 2 |
| Yuan, M | 2 |
| Gaspar, VM | 1 |
| Gonçalves, C | 1 |
| de Melo-Diogo, D | 1 |
| Costa, EC | 1 |
| Queiroz, JA | 1 |
| Pichon, C | 1 |
| Sousa, F | 1 |
| Correia, IJ | 1 |
| Yang, C | 1 |
| Chen, H | 1 |
| Zhao, J | 1 |
| Pang, X | 1 |
| Xi, Y | 1 |
| Zhai, G | 1 |
| Li, Y | 3 |
| Wu, H | 1 |
| Yang, X | 1 |
| Jia, M | 1 |
| Huang, Y | 1 |
| Lin, J | 1 |
| Wu, S | 1 |
| Hou, Z | 1 |
| Wei, Z | 1 |
| Tian, P | 1 |
| Liu, X | 1 |
| Zhou, B | 1 |
| Fornaguera, C | 2 |
| Grijalvo, S | 1 |
| Galán, M | 1 |
| Fuentes-Paniagua, E | 1 |
| de la Mata, FJ | 1 |
| Gómez, R | 1 |
| Eritja, R | 1 |
| Calderó, G | 2 |
| Solans, C | 2 |
| Szymonowicz, M | 1 |
| Rybak, Z | 1 |
| Witkiewicz, W | 1 |
| Pezowicz, C | 1 |
| Filipiak, J | 1 |
| Mitjans, M | 1 |
| Vinardell, MP | 1 |
| Vauthier, C | 1 |
| Omar, HR | 1 |
| Mirsaeidi, M | 1 |
| Socias, S | 1 |
| Sprenker, C | 1 |
| Caldeira, C | 1 |
| Camporesi, EM | 1 |
| Mangar, D | 1 |
| Pillai, GJ | 1 |
| Greeshma, MM | 1 |
| Menon, D | 1 |
| Levin, E | 1 |
| Chen, D | 2 |
| Hansen, A | 1 |
| Turner, TR | 1 |
| Kurach, J | 1 |
| Reidel, A | 1 |
| Boecker, WF | 1 |
| Acker, JP | 1 |
| Brisbois, EJ | 1 |
| Major, TC | 1 |
| Goudie, MJ | 1 |
| Meyerhoff, ME | 1 |
| Bartlett, RH | 1 |
| Handa, H | 1 |
| Eckhard, LH | 1 |
| Houri-Haddad, Y | 1 |
| Sol, A | 1 |
| Zeharia, R | 1 |
| Shai, Y | 1 |
| Beyth, S | 1 |
| Domb, AJ | 1 |
| Bachrach, G | 1 |
| Beyth, N | 1 |
| Mambrini, G | 1 |
| Mandolini, M | 1 |
| Rossi, L | 1 |
| Pierigè, F | 1 |
| Capogrossi, G | 1 |
| Salvati, P | 1 |
| Serafini, S | 1 |
| Benatti, L | 1 |
| Magnani, M | 1 |
| Gulliksson, H | 1 |
| Meinke, S | 1 |
| Ravizza, A | 1 |
| Höglund, P | 1 |
| Bontekoe, IJ | 1 |
| van der Meer, PF | 1 |
| de Korte, D | 1 |
| Radwan, MA | 1 |
| AlQuadeib, BT | 1 |
| Šiller, L | 1 |
| Wright, MC | 1 |
| Horrocks, B | 1 |
| Cruz, J | 1 |
| Flórez, J | 1 |
| Torres, R | 1 |
| Urquiza, M | 1 |
| Gutiérrez, JA | 1 |
| Guzmán, F | 1 |
| Ortiz, CC | 1 |
| Nguyen, J | 1 |
| Steele, TW | 1 |
| Merkel, O | 1 |
| Reul, R | 1 |
| Kissel, T | 1 |
| Bang, JY | 1 |
| Song, CE | 1 |
| Kim, C | 1 |
| Park, WD | 1 |
| Cho, KR | 1 |
| Kim, PI | 1 |
| Lee, SR | 1 |
| Chung, WT | 1 |
| Choi, KC | 1 |
| Italia, JL | 1 |
| Yahya, MM | 1 |
| Singh, D | 1 |
| Ravi Kumar, MN | 1 |
| Hu, W | 1 |
| Huang, ZM | 1 |
| Meng, SY | 1 |
| He, CL | 1 |
| Makley, AT | 1 |
| Goodman, MD | 1 |
| Friend, LA | 1 |
| Johannigman, JA | 1 |
| Dorlac, WC | 1 |
| Lentsch, AB | 1 |
| Pritts, TA | 1 |
| Jain, JP | 1 |
| Kumar, N | 1 |
| Lu, P | 1 |
| Cao, L | 1 |
| Liu, Y | 1 |
| Wu, X | 1 |
| Zhou, Q | 1 |
| Zhang, Z | 1 |
| Chen, T | 1 |
| Guo, X | 1 |
| Zhou, S | 1 |
| Sullivan, R | 1 |
| Santarpia, P | 1 |
| Lavender, S | 1 |
| Gittins, E | 1 |
| Liu, Z | 1 |
| Anderson, MH | 1 |
| He, J | 1 |
| Shi, W | 1 |
| Eckert, R | 1 |
| Thasneem, YM | 1 |
| Sajeesh, S | 1 |
| Sharma, CP | 1 |
| Watts, JA | 1 |
| Gellar, MA | 1 |
| Fulkerson, MB | 1 |
| Das, SK | 1 |
| Kline, JA | 1 |
| Yallapu, MM | 1 |
| Ebeling, MC | 1 |
| Chauhan, N | 1 |
| Jaggi, M | 1 |
| Chauhan, SC | 1 |
| Gupta, S | 1 |
| Agarwal, A | 1 |
| Gupta, NK | 1 |
| Saraogi, G | 1 |
| Agrawal, H | 1 |
| Surolia, R | 1 |
| Pachauri, M | 1 |
| Ghosh, PC | 1 |
| Kong, M | 1 |
| Cheng, XJ | 1 |
| Dang, QF | 1 |
| Zhou, X | 1 |
| Wei, YN | 1 |
| Chen, XG | 1 |
| Xu, H | 1 |
| Nguyen, KT | 1 |
| Brilakis, ES | 1 |
| Yang, J | 1 |
| Fuh, E | 1 |
| Banerjee, S | 1 |
| Van de Ven, H | 1 |
| Paulussen, C | 1 |
| Feijens, PB | 1 |
| Matheeussen, A | 1 |
| Rombaut, P | 1 |
| Kayaert, P | 1 |
| Van den Mooter, G | 1 |
| Weyenberg, W | 1 |
| Cos, P | 1 |
| Maes, L | 1 |
| Ludwig, A | 1 |
| Zelenak, C | 1 |
| Pasham, V | 1 |
| Jilani, K | 1 |
| Tripodi, PM | 1 |
| Rosaclerio, L | 1 |
| Pathare, G | 1 |
| Lupescu, A | 1 |
| Faggio, C | 1 |
| Qadri, SM | 1 |
| Lang, F | 1 |
| Xiong, Y | 1 |
| Jiang, W | 1 |
| Sun, C | 1 |
| Ouahab, A | 1 |
| Tu, J | 1 |
| Essa, S | 1 |
| Louhichi, F | 1 |
| Raymond, M | 1 |
| Hildgen, P | 1 |
| Yang, F | 1 |
| Chen, W | 1 |
| Liu, J | 1 |
| Huang, W | 1 |
| Jin, M | 1 |
| Gao, Z | 1 |
| Thomas, S | 1 |
| Hancock, V | 1 |
| Ciborowski, M | 1 |
| Lipska, A | 1 |
| Godzien, J | 1 |
| Ferrarini, A | 1 |
| Korsak, J | 1 |
| Radziwon, P | 1 |
| Tomasiak, M | 1 |
| Barbas, C | 1 |
| Birri, DJ | 1 |
| Brede, DA | 1 |
| Tessema, GT | 1 |
| Nes, IF | 1 |
| Burda, G | 1 |
| Trittenwein, H | 1 |
| Carole, H | 1 |
| Trittenwein, G | 1 |
| Carlson, GA | 1 |
| Dragoo, JL | 1 |
| Samimi, B | 1 |
| Bruckner, DA | 1 |
| Bernard, GW | 1 |
| Hedrick, M | 1 |
| Benhaim, P | 1 |
| Kim, D | 1 |
| El-Shall, H | 1 |
| Dennis, D | 1 |
| Morey, T | 1 |
| Yi, Y | 1 |
| Yoon, HJ | 1 |
| Kim, BO | 1 |
| Shim, M | 1 |
| Kim, SO | 1 |
| Hwang, SJ | 1 |
| Seo, MH | 1 |
| Picker, SM | 1 |
| Radojska, SM | 1 |
| Gathof, BS | 1 |
| Niinistö, K | 1 |
| Raekallio, M | 1 |
| Sankari, S | 1 |
| Qiao, M | 1 |
| Hao, T | 1 |
| Zhao, X | 1 |
| Hu, H | 1 |
| Ma, X | 1 |
| Cenni, E | 1 |
| Granchi, D | 1 |
| Avnet, S | 1 |
| Fotia, C | 1 |
| Salerno, M | 1 |
| Micieli, D | 1 |
| Sarpietro, MG | 1 |
| Pignatello, R | 1 |
| Castelli, F | 1 |
| Baldini, N | 1 |
| Riede, U | 1 |
| Sandritter, W | 1 |
| Mittermayer, C | 1 |
| Jausel-Hüsken, S | 1 |
| Deuticke, B | 1 |
| Heaton, WA | 1 |
| Holme, S | 1 |
| Smith, K | 1 |
| Brecher, ME | 1 |
| Pineda, A | 1 |
| AuBuchon, JP | 2 |
| Nelson, E | 1 |
| Högman, CF | 2 |
| Eriksson, L | 2 |
| Gong, J | 1 |
| Högman, AB | 1 |
| Vikholm, K | 1 |
| Debrauwere, J | 1 |
| Payrat, JM | 1 |
| Stewart, M | 1 |
| Kogawa, H | 1 |
| Satoh, M | 1 |
| Mitsudo, M | 1 |
| Higuchi, T | 1 |
| Kageyama, K | 1 |
| Thin, AG | 1 |
| Hamzah, Z | 1 |
| FitzGerald, MX | 1 |
| McLoughlin, P | 1 |
| Freaney, R | 1 |
| Ecker, T | 1 |
| Hitzler, WE | 1 |
| Pickard, CA | 1 |
| Herschel, LH | 1 |
| Roger, JC | 1 |
| Tracy, JE | 1 |
| Purmal, A | 1 |
| Chapman, J | 1 |
| Ackerman, S | 1 |
| Beach, KJ | 1 |
| Goto, I | 1 |
| Shimizu, T | 1 |
| Maede, Y | 1 |
| Foxdal, P | 1 |
| Bergqvist, Y | 1 |
| Eckerbom, S | 1 |
| Sandhagen, B | 1 |
| Ericson, A | 1 |
| Reppucci, AJ | 1 |
| Corbucci, GG | 1 |
| Angué, M | 1 |
| Chatelain, P | 1 |
| Fiabane, S | 1 |
| Domy, M | 1 |
| Guignier, F | 1 |
| Richaud, P | 1 |
| Petrenko, IuM | 1 |
| Vladimirov, IuA | 1 |
| Stephan, H | 1 |
| Larsen, R | 1 |
| Sonntag, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Feasibility Study to Consider the Relationship Between Markers of Red Cell Damage, Inflammation and the Recovery Process of Newborns Requiring Extracorporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN): Mi-ECM[NCT02940327] | 24 participants (Actual) | Observational | 2016-02-19 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO is discontinued
| Intervention | ml (Mean) |
|---|---|
| 7+ Days | 289.6 |
| <7 Days | 479.2 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.5 |
| <7 Days | 0.84 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.02 |
| <7 Days | 0.38 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO decannulation
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.01 |
| <7 Days | 0.40 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 0.29 |
| <7 Days | 0.27 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 0.72 |
| <7 Days | 0.59 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | percent change (Mean) |
|---|---|
| 7+ Days | 1.90 |
| <7 Days | 1.13 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.56 |
| <7 Days | 0.6 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.11 |
| <7 Days | 0.64 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 0.73 |
| <7 Days | 0.4 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.55 |
| <7 Days | 0.93 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 8.7 |
| <7 Days | 4.65 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.2 |
| <7 Days | 2.27 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 7.34 |
| <7 Days | 1.89 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.26 |
| <7 Days | 0.92 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.31 |
| <7 Days | 1.9 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 109.64 |
| <7 Days | 112.07 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 109.25 |
| <7 Days | 110.23 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 114.30 |
| <7 Days | 109.43 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 112.56 |
| <7 Days | 113.08 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 112.90 |
| <7 Days | 109.89 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: baseline
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 151.5 |
| <7 Days | 145.4 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: > 7 days or did not survive to discharge
| Intervention | hours (Median) |
|---|---|
| 7+ Days | 292 |
| <7 Days | 80 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 7.89 |
| <7 Days | 6.96 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 9.54 |
| <7 Days | 7.44 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 3.71 |
| <7 Days | 3.11 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 2.13 |
| <7 Days | 1.81 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 5.51 |
| <7 Days | 5.88 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO is discontinued
| Intervention | Participants (Count of Participants) |
|---|---|
| 7+ Days | 10 |
| <7 Days | 10 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: >7 days or did not survive to discharge
| Intervention | participants (Number) |
|---|---|
| 7+ Days | 3 |
| <7 Days | 0 |
1 review available for lactic acid and Hemolysis
| Article | Year |
|---|---|
Circulatory shock: a review.
Topics: Adenosine Triphosphate; Blood Coagulation; Blood Pressure; Cardiac Output; Glycolysis; Hemolysis; Hu | 1981 |
3 trials available for lactic acid and Hemolysis
| Article | Year |
|---|---|
Lactate determination in exercise testing using an electrochemical analyser: with or without blood lysis?
Topics: Adult; Electrochemistry; Exercise Test; Hemolysis; Humans; Lactic Acid; Male; Oxygen Consumption | 1999 |
Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study.
Topics: 2,3-Diphosphoglycerate; ABO Blood-Group System; Adenosine Triphosphate; Adult; Blood Donors; Blood G | 2002 |
The role of reduced glutathione during the course of acute haemolysis in glucose-6-phosphate dehydrogenase deficient patients: clinical and pharmacodynamic aspects.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; Cell Hypoxia; Double-Blind Met | 1990 |
80 other studies available for lactic acid and Hemolysis
| Article | Year |
|---|---|
Non-invasive monitoring of red blood cells during cold storage using handheld Raman spectroscopy.
Topics: Adult; Blood Glucose; Blood Preservation; Blood Safety; Cold Temperature; Erythrocytes; Feasibility | 2021 |
Assessment of penetration potential of pH responsive double walled biodegradable nanogels coated with eucalyptus oil for the controlled delivery of 5-fluorouracil: In vitro and ex vivo studies.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Survival; Chitosan; Delayed-Act | 2017 |
Red blood cells ageing markers: a multi-parametric analysis.
Topics: Blood Preservation; Cell-Derived Microparticles; Citrates; Erythrocyte Aging; Erythrocytes; Glucose; | 2017 |
PLGA Nanoparticles and Polysorbate-80-Coated PLGA Nanoparticles Increase the In vitro Antioxidant Activity of Melatonin.
Topics: Antioxidants; Drug Liberation; Hemolysis; In Vitro Techniques; Lactic Acid; Melatonin; Nanoparticles | 2018 |
Allopurinol attenuates acute kidney injury following Bothrops jararaca envenomation.
Topics: Acute Kidney Injury; Allopurinol; Animals; Antioxidants; Bothrops; Crotalid Venoms; Glomerular Filtr | 2017 |
In vitro assessment of quality of citrate-phosphate-dextrose-adenine-1 preserved feline blood collected by a commercial closed system.
Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Animals; Blood Cell Count; Blood Preservation; Blood | 2018 |
Hepatitis B Antigen Loaded Biodegradable Polymeric Nanoparticles: Formulation Optimization and In-vivo Immunization in BALB/c Mice.
Topics: Adjuvants, Immunologic; Alum Compounds; Animals; Cell Proliferation; Drug Compounding; Drug Liberati | 2018 |
Comparison of automated and manual methods for washing red blood cells.
Topics: Adenine; Automation; Blood Glucose; Blood Preservation; Erythrocyte Transfusion; Erythrocyte Volume; | 2018 |
A novel protocol for cryopreservation of paediatric red blood cell units allows increased availability of rare blood types.
Topics: Blood Group Antigens; Blood Preservation; Child; Cryopreservation; Erythrocytes; Freezing; Glucose; | 2019 |
Synthesis and characterization of multi-functional linear-dendritic block copolymer for intracellular delivery of antitumor drugs.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Dendrimers; Docetaxel; Drug Delivery | 2013 |
Bio-responsive chitin-poly(L-lactic acid) composite nanogels for liver cancer.
Topics: Cell Survival; Chitin; Doxorubicin; Hemolysis; Hep G2 Cells; Humans; Lactic Acid; Liver Neoplasms; N | 2014 |
Dual targeted polymeric nanoparticles based on tumor endothelium and tumor cells for enhanced antitumor drug delivery.
Topics: Animals; Antineoplastic Agents; Apoptosis; CD13 Antigens; Cell Cycle; Cell Proliferation; Cells, Cul | 2014 |
Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment.
Topics: 2,3-Diphosphoglycerate; Acridines; Adenosine Triphosphate; Alkylating Agents; Blood Preservation; Bl | 2014 |
Preparation and in vitro evaluation of novel poly(anhydride-ester)-based amphiphilic copolymer curcumin-loaded micelles.
Topics: Animals; Cell Cycle; Cell Death; Curcumin; Endocytosis; Esters; HeLa Cells; Hemolysis; Humans; Hydro | 2014 |
The biocompatibility evaluation of mPEG-PLGA-PLL copolymer and different LA/GA ratio effects for biocompatibility.
Topics: Adsorption; Animals; Blood Coagulation Tests; Cell Line; Complement System Proteins; Dose-Response R | 2014 |
In vitro and in vivo analysis of the antithrombotic and toxicological profile of new antiplatelets N-acylhydrazone derivatives and development of nanosystems: determination of novel NAH derivatives antiplatelet and nanotechnological approach.
Topics: Adult; Animals; Blood Coagulation; Chlorocebus aethiops; Drug Carriers; Hemolysis; Humans; Hydrazine | 2014 |
Hemocompatibility evaluation of small elastomeric hollow fiber membranes as vascular substitutes.
Topics: Adsorption; Biocompatible Materials; Blood Proteins; Blood Vessel Prosthesis; Elastomers; Hemolysis; | 2014 |
Development and evaluation of paclitaxel loaded PLGA:poloxamer blend nanoparticles for cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Discovery; Drug Stability; Hem | 2014 |
The in vitro biological properties of Mg-Zn-Sr alloy and superiority for preparation of biodegradable intestinal anastomosis rings.
Topics: Adult; Alloys; Anastomosis, Surgical; Animals; Anti-Bacterial Agents; Biocompatible Materials; Cell | 2014 |
Preparation, characterization, in vitro release and degradation of cathelicidin-BF-30-PLGA microspheres.
Topics: Antimicrobial Cationic Peptides; Apoptosis; Cathelicidins; Cell Proliferation; Cells, Cultured; Chro | 2014 |
Poly(2-ethyl-2-oxazoline)-PLA-g-PEI amphiphilic triblock micelles for co-delivery of minicircle DNA and chemotherapeutics.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; DNA, Circular; Doxorubicin | 2014 |
Development of a folate-modified curcumin loaded micelle delivery system for cancer targeting.
Topics: Animals; Cell Death; Cell Survival; Curcumin; Drug Delivery Systems; Endocytosis; Folic Acid; Hemoly | 2014 |
Mitomycin C-soybean phosphatidylcholine complex-loaded self-assembled PEG-lipid-PLA hybrid nanoparticles for targeted drug delivery and dual-controlled drug release.
Topics: Animals; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Glycine max; HeLa Cells; Hemolysis; | 2014 |
Hemocompatibility and selective cell fate of polydopamine-assisted heparinized PEO/PLLA composite coating on biodegradable AZ31 alloy.
Topics: Alloys; Blood Platelets; Cell Proliferation; Coated Materials, Biocompatible; Corrosion; Electrolysi | 2014 |
Novel non-viral gene delivery systems composed of carbosilane dendron functionalized nanoparticles prepared from nano-emulsions as non-viral carriers for antisense oligonucleotides.
Topics: Cell Line, Tumor; Cell Survival; Dendrimers; Emulsions; Erythrocytes; Gene Transfer Techniques; Hemo | 2015 |
In vitro hemocompatibility studies of (poly(L-lactide) and poly(L-lactide-co-glycolide) as materials for bioresorbable stents manufacture.
Topics: Absorbable Implants; Biocompatible Materials; Blood Coagulation; Blood Platelets; Erythrocyte Count; | 2014 |
Interactions of PLGA nanoparticles with blood components: protein adsorption, coagulation, activation of the complement system and hemolysis studies.
Topics: Adsorption; Animals; Blood Coagulation; Cattle; Complement Activation; Hemolysis; Humans; Lactic Aci | 2015 |
Plasma Free Hemoglobin Is an Independent Predictor of Mortality among Patients on Extracorporeal Membrane Oxygenation Support.
Topics: Aged; Biomarkers; Blood Transfusion; Cardiomyopathies; Extracorporeal Membrane Oxygenation; Female; | 2015 |
Impact of poly(lactic-co-glycolic acid) nanoparticle surface charge on protein, cellular and haematological interactions.
Topics: Blood Coagulation; Hemolysis; Lactic Acid; Microscopy, Electron, Scanning; Nanoparticles; Polyglycol | 2015 |
An investigation of red blood cell concentrate quality during storage in paediatric-sized polyvinylchloride bags plasticized with alternatives to di-2-ethylhexyl phthalate (DEHP).
Topics: Adenosine Triphosphate; Blood Cell Count; Blood Gas Analysis; Blood Preservation; Diethylhexyl Phtha | 2016 |
Attenuation of thrombosis and bacterial infection using dual function nitric oxide releasing central venous catheters in a 9day rabbit model.
Topics: Animals; Bacterial Adhesion; Bacterial Infections; Central Venous Catheters; Colony Count, Microbial | 2016 |
Sustained Release of Antibacterial Lipopeptides from Biodegradable Polymers against Oral Pathogens.
Topics: Animals; Anti-Bacterial Agents; Biocompatible Materials; Biofilms; Castor Oil; Cell Membrane; Colori | 2016 |
Ex vivo encapsulation of dexamethasone sodium phosphate into human autologous erythrocytes using fully automated biomedical equipment.
Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Ataxia Telangiectasia; Automation; Case-Control Stud | 2017 |
Storage of red blood cells in a novel polyolefin blood container: a pilot in vitro study.
Topics: 2,3-Diphosphoglycerate; Adenine; Adult; Aged; Blood Glucose; Blood Preservation; Erythrocyte Count; | 2017 |
Critical re-appraisal of blood component quality after overnight hold of whole blood outside current room temperature limits.
Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Blood Platelets; Blood Preservation; Erythrocytes; H | 2017 |
Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.
Topics: Administration, Oral; Amphotericin B; Animals; Antifungal Agents; Biological Availability; Biomarker | 2017 |
Antimicrobial activity of a new synthetic peptide loaded in polylactic acid or poly(lactic-co-glycolic) acid nanoparticles against Pseudomonas aeruginosa, Escherichia coli O157:H7 and methicillin resistant Staphylococcus aureus (MRSA).
Topics: Amino Acid Sequence; Anti-Infective Agents; Drug Liberation; Escherichia coli O157; Hemolysis; Human | 2017 |
Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy.
Topics: Administration, Inhalation; Aerosols; Binding, Competitive; Cell Line; Gene Knockdown Techniques; Ge | 2008 |
Cytotoxicity of amphotericin B-incorporated polymeric micelles composed of poly(DL-lactide-co-glycolide)/dextran graft copolymer.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Chemistry, Pharmaceutical; Dextrans; Drug Compo | 2008 |
Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone.
Topics: Amphotericin B; Animals; Antifungal Agents; Biological Availability; Blood Urea Nitrogen; Creatine; | 2009 |
Fabrication and characterization of chitosan coated braided PLLA wire using aligned electrospun fibers.
Topics: Animals; Biocompatible Materials; Chitosan; Electronics; Equipment Design; Erythrocytes; Hemolysis; | 2009 |
Murine blood banking: characterization and comparisons to human blood.
Topics: Animals; Blood Banking; Blood Preservation; Erythrocytes; Hemolysis; Humans; Lactic Acid; Male; Mice | 2010 |
Development of amphotericin B loaded polymersomes based on (PEG)(3)-PLA co-polymers: Factors affecting size and in vitro evaluation.
Topics: Amphotericin B; Animals; Antifungal Agents; Biological Availability; Drug Carriers; Drug Compounding | 2010 |
Evaluation of magnesium ions release, biocorrosion, and hemocompatibility of MAO/PLLA-modified magnesium alloy WE42.
Topics: Alloys; Blood Coagulation; Coated Materials, Biocompatible; Corrosion; Dielectric Spectroscopy; Eval | 2011 |
Preparation and characterization of thermosensitive pluronic F127-b-poly(ɛ-caprolactone) mixed micelles.
Topics: Animals; Cattle; Cell Survival; Cells, Cultured; Doxorubicin; Drug Carriers; Hemolysis; Hep G2 Cells | 2011 |
Clinical efficacy of a specifically targeted antimicrobial peptide mouth rinse: targeted elimination of Streptococcus mutans and prevention of demineralization.
Topics: Adolescent; Adult; Aged; Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacterial | 2011 |
Effect of thiol functionalization on the hemo-compatibility of PLGA nanoparticles.
Topics: Adsorption; Biocompatible Materials; Cell Adhesion; Cell Line; Complement Activation; Drug Carriers; | 2011 |
Arginase depletes plasma l-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism.
Topics: Animals; Arginase; Arginine; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Enzym | 2012 |
Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes.
Topics: Analysis of Variance; Blood Proteins; Cell Line, Tumor; Curcumin; Drug Carriers; Erythrocytes; Hemol | 2011 |
Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir.
Topics: Acyclovir; Animals; Antiviral Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug C | 2013 |
Preparation and characterization of monensin loaded PLGA nanoparticles: in vitro anti-malarial activity against Plasmodium falciparum.
Topics: Antimalarials; Calorimetry, Differential Scanning; Cells, Cultured; Emulsions; Erythrocytes; Hemolys | 2012 |
Preparation of biocompatible chitosan grafted poly(lactic acid) nanoparticles.
Topics: Biocompatible Materials; Cell Line; Chitosan; Hemolysis; Humans; Lactic Acid; Nanoparticles; Polyest | 2012 |
Enhanced endothelialization of a new stent polymer through surface enhancement and incorporation of growth factor-delivering microparticles.
Topics: Antibodies; Antigens, CD34; Blood Coagulation; Blood Platelets; Cell Adhesion; Cell Proliferation; C | 2012 |
PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Cell Line; Colony Count, Microbial; Eryth | 2012 |
Tanshinone IIA stimulates erythrocyte phosphatidylserine exposure.
Topics: Abietanes; Adenosine Triphosphate; Calcium; Cell Death; Cell Size; Ceramides; Erythrocyte Membrane; | 2012 |
A poly(γ, L-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatography; Cisplatin; Citric Acid; Drug Deliv | 2012 |
Improved antifungal activity of itraconazole-loaded PEG/PLA nanoparticles.
Topics: Antifungal Agents; Calorimetry, Differential Scanning; Hemolysis; Itraconazole; Lactic Acid; Nanopar | 2013 |
A novel monomethoxy polyethylene glycol-polylactic acid polymeric micelles with higher loading capacity for docetaxel and well-reconstitution characteristics and its anti-metastasis study.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Guinea Pi | 2012 |
The 30 minute rule for red blood cells: in vitro quality assessment after repeated exposure to 30°C.
Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Blood Banks; Blood Preservation; Blood Specimen Coll | 2013 |
Combination of LC-MS- and GC-MS-based metabolomics to study the effect of ozonated autohemotherapy on human blood.
Topics: Adult; Antioxidants; Biomarkers; Blood Cell Count; Chromatography, Liquid; Gas Chromatography-Mass S | 2012 |
Bacteriocin production, antibiotic susceptibility and prevalence of haemolytic and gelatinase activity in faecal lactic acid bacteria isolated from healthy Ethiopian infants.
Topics: Bacteriocins; Cytotoxins; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus; Ethiopia; Feces; | 2013 |
Testing of extracorporeal membrane oxygenation circuit related hemolysis using long-term stored packed red cells and fresh frozen plasma.
Topics: Blood Glucose; Erythrocyte Transfusion; Erythrocytes; Extracorporeal Membrane Oxygenation; Hemoglobi | 2004 |
Bacteriostatic properties of biomatrices against common orthopaedic pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Biocompatible Materials; Cell Division; Collagen; Hemolysis; Hyalur | 2004 |
Interaction of PLGA nanoparticles with human blood constituents.
Topics: Blood; Blood Chemical Analysis; Blood Coagulation; Drug Carriers; Electrolytes; Hemolysis; Humans; H | 2005 |
A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics.
Topics: Animals; Antifungal Agents; Area Under Curve; Chemical Phenomena; Chemistry, Pharmaceutical; Chemist | 2007 |
In vitro quality of red blood cells (RBCs) collected by multicomponent apheresis compared to manually collected RBCs during 49 days of storage.
Topics: Adenosine Triphosphate; Adult; Blood Component Removal; Blood Preservation; Blood Specimen Collectio | 2007 |
Storage of equine red blood cells as a concentrate.
Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Animals; Blood Preservation; Erythrocytes; Hemolysis | 2008 |
Effect of bee venom peptide-copolymer interactions on thermosensitive hydrogel delivery systems.
Topics: Algorithms; Bee Venoms; Drug Delivery Systems; Excipients; Hemolysis; Humans; Hydrogels; In Vitro Te | 2007 |
Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate.
Topics: Alendronate; Alkaline Phosphatase; Cell Survival; Hemolysis; Humans; Lactic Acid; Leukocyte Count; M | 2008 |
General and transport properties of hypotonic and isotonic preparations of resealed erythrocyte ghosts.
Topics: Ammonium Chloride; Arabinose; Cell Membrane Permeability; Erythritol; Erythrocyte Membrane; Erythroc | 1981 |
Effects of 3-5 log10 pre-storage leucocyte depletion on red cell storage and metabolism.
Topics: Adenosine Triphosphate; Blood Glucose; Blood Preservation; Cell Separation; Erythrocytes; Filtration | 1994 |
Half-strength citrate CPD combined with a new additive solution for improved storage of red blood cells suitable for clinical use.
Topics: 2,3-Diphosphoglycerate; Blood Donors; Blood Preservation; Citrates; Diphosphoglyceric Acids; Erythro | 1993 |
Effect of lactic acid on water content and osmotic fragility of erythrocytes in vivo.
Topics: Animals; Body Water; Centrifugation; Chromatography, Gas; Erythrocyte Membrane; Erythrocytes; Hemoly | 1997 |
Effect of 6-hour exposure to 20 degrees C on the ATP content and other biochemical measures of CPDA-1 packed red cells.
Topics: Adenine; Adenosine Triphosphate; Anticoagulants; Blood Glucose; Blood Preservation; Citrates; Cryopr | 2000 |
L-sorbose does not cause hemolysis in dog erythrocytes with inherited high Na, K-ATPase activity.
Topics: Adenosine Triphosphate; Animals; Dogs; Erythrocytes; Hemolysis; Humans; Lactates; Lactic Acid; Male; | 1992 |
Improving lactate analysis with the YSI 2300 GL: hemolyzing blood samples makes results comparable with those for deproteinized whole blood.
Topics: Biosensing Techniques; Blood Chemical Analysis; Drug Stability; Hemolysis; Humans; Indicators and Re | 1992 |
Storage of saline-adenine-glucose-mannitol-suspended red cells in a new plastic container: polyvinylchloride plasticized with butyryl-n-trihexyl-citrate.
Topics: 2,3-Diphosphoglycerate; Adenine; Adenine Nucleotides; Adenosine Triphosphate; Blood Glucose; Blood P | 1991 |
[Viability of human red blood cells preserved for 35 days after leukocyte depletion (in vitro study)].
Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Blood Component Removal; Blood Glucose; Blood Preser | 1989 |
[Hemoglobin aggregation in erythrocytes as a factor in the disturbance of their structural and functional integrity].
Topics: Animals; Erythrocyte Aggregation; Erythrocytes; Hemoglobins; Hemolysis; Hot Temperature; Lactates; L | 1987 |
[The effect of rewarming of stored blood on plasma value and erythrocytes].
Topics: Blood Cell Count; Blood Preservation; Blood Viscosity; Cholesterol; Erythrocyte Count; Hemoglobins; | 1985 |